Invesco
MNPR icon

Invesco’s Monopar Therapeutics MNPR Stock Holding History

Invesco’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$218K Buy
+2,356
New +$146K ﹤0.01% 3560
2026
Q1 		– Sell
-3,355
Closed -$219K – 3795
2025
Q4 		$219K Buy
+3,355
New +$274K ﹤0.01% 3494

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Invesco's MNPR Position: Q2 2026 in Review

Invesco opened a new position in Monopar Therapeutics (MNPR) in Q2 2026: 2,356 shares worth $218K. The stake represents ﹤0.01% of the portfolio and ranks #3560 among its holdings. This is a return to the name: Invesco previously reported a position in MNPR as recently as Q4 2025.

Invesco first reported a position in MNPR in Q4 2025 and has held it in 2 quarters since. The position peaked at $219K in Q4 2025. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Invesco held 2,356 shares of Monopar Therapeutics worth $218K as of Q2 2026.
  • Monopar Therapeutics was a new Invesco position in Q2 2026.
  • Monopar Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3560 holding.
  • Invesco first reported a position in Monopar Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Invesco's Monopar Therapeutics position peaked at $219K in Q4 2025.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.